Macrogenics: Pay

Macrogenics paid its 4 named executives $5.4M in total in FY2025 (Dec). CEO Eric Risser was paid $2.1M of that.

Pay$100 in the stock at the end of FY24 → $50
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Eric RisserPresident, Chief Executive Officer and Director
FY2025 (Dec)
1 year
Ezio BonviniSenior Vice President, Research and Chief Scientific Officer
FY2025 (Dec)
1 year
James KarrelsSenior Vice President and Chief Financial Officer
FY2025 (Dec)
FY2022 (Dec)
2 years
Scott Koenig, M.D., Ph.D.Former Chief Executive Officer and current Director
FY2025 (Dec)
FY2022 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $5.0M. CEO pay of Macrogenics for that year is not on file.

  1. 1Scholar Rock Holding
  2. 2Cogent Biosciences
  3. 3Arcus Biosciences
  4. 4Zymeworks
  5. 5Precigen
  6. 6Rigel Pharmaceuticals
  7. 7Regenxbio
  8. 8Fate Therapeutics
  9. 9Inovio Pharmaceuticals
  10. 10Agenus
  11. 11MacrogenicsNot disclosed
  12. 122seventy bioNot disclosed
  13. 13Adaptimmune TherapeuticsNot disclosed
  14. 14G1 TherapeuticsNot disclosed
  15. 15Karyopharm TherapeuticsNot disclosed
  16. 16Mersana TherapeuticsNot disclosed
  17. 17Sutro BiopharmaNot disclosed
  18. 18XencorNot disclosed
  19. 19Y-mAbs TherapeuticsNot disclosed
  20. 20iTeos TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.